Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT02943798 Not yet recruiting - Clinical trials for Pulmonary Large Cell Neuroendocrine Carcinoma

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.

NCT ID: NCT02916368 Not yet recruiting - Clinical trials for Carcinoma, Squamous Cell

The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma

Start date: January 2017
Phase: Phase 1
Study type: Observational

Head and neck Squamous Cell Carcinoma (HNSCC) is one of the most common head and neck malignant tumors .Investigators found that several patients with early TNM stage and poor differentiated HNSCC had poor prognosis, yet someone with advanced TNM stage and well differentiated HNSCC had good prognosis. Hence, Investigators suggested that prognosis factors and survival rates probably related to the differentiation of HNSCC, and prognosis factor of poorly differentiated HNSCC were rare discussed and controversy. Investigating the prognostic factors of poorly differentiated HNSCC is undoubtedly crucial.

NCT ID: NCT02915965 Not yet recruiting - Clinical trials for Stage II and III Esophageal Squamous Cell Carcinoma

A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether docetaxel, cisplatin, and capecitabine (DCX) are effective as the neoadjuvant chemotherapy before esophagectomy in patients with loco-regional esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT02907710 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: October 2016
Phase: Phase 3
Study type: Interventional

A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic and side effects of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locoregionally advanced nasopharyngeal carcinoma with high efficacy and low toxicity.

NCT ID: NCT02907606 Not yet recruiting - Lung Neoplasms Clinical Trials

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Start date: September 2016
Phase: N/A
Study type: Observational [Patient Registry]

This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.

NCT ID: NCT02854410 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients

Start date: August 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether dietary nitrate supplementation could improve the salivary flow for nasopharyngeal carcinoma patients receiving concurrent chemo-radiation therapy.

NCT ID: NCT02847767 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Dynamic Contrast Enhanced HCC SABR Liver Study

Start date: July 2016
Phase: N/A
Study type: Interventional

The high dose per fraction (>10Gy/fraction) used in Stereotactic Ablative Body Radiotherapy (SABR) has been shown to be more effective at local tumor control than treatments employing more conventional dose fractions. The mechanisms for this are currently under debate. One possible mechanism for this increased effectiveness is that high dose/fraction causes significant vascular damage to the tumor. This study hopes to measure vascular integrity pre and post SABR treatment using kinetic models obtained from dynamic contrast enhanced CT.

NCT ID: NCT02813096 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients

Start date: October 2016
Phase: N/A
Study type: Interventional

This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection

NCT ID: NCT02787915 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

DC1s-CTL Cellular Therapy for Renal Cell Carcinoma

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is to evaluate the safety and effectiveness of autologous type-1 polarized dendritic cell vaccines (patients' autologous DC1s loaded with multiple antigens CTL epitope peptide complexes), after radical resection for patients with stage III-IV renal cell carcinoma. Autologous cytotoxic of T lymphocytes (CTL) induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .

NCT ID: NCT02786641 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: August 2016
Phase: Phase 3
Study type: Interventional

The investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma.